Skip to content
Unrated Drug recall · FDA · Published December 16, 2024

Somerset Therapeutics Atropine Sulfate Ophthalmic Solution Recall: Impurities Risk

Somerset Therapeutics recalls 1% Atropine Sulf: Impurities may degrade product quality. Rx only, 5mL bottles. Check NDC 70069-716-01 and lot A240211.

🇺🇸 FDA recall #D-0169-2025DrugSomerset Therapeutics ›
Take action

Contact the company

Recalling firmSOMERSET THERAPEUTICS LLC300 Franklin Square Dr · Somerset, NJ 08873-4187
✎ GovInfoNow plain-language explainer

Somerset Therapeutics is recalling 1% Atropine Sulfate Ophthalmic Solution 5mL bottles due to potential impurities or degradation. This could affect product safety for eye treatments. Patients with prescriptions should contact their doctor. Read more at govinfonow.com/recall/32361-somerset-therapeutics-atropine-sulfate-ophthalmic-solution-recall-impurities-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/32361-somerset-therapeutics-atropine-sulfate-ophthalmic-solution-recall-impurities-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0169-2025

Cite this page

“Somerset Therapeutics Atropine Sulfate Ophthalmic Solution Recall: Impurities Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32361-somerset-therapeutics-atropine-sulfate-ophthalmic-solution-recall-impurities-risk. Based on FDA recall #D-0169-2025 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0169-2025%22&limit=1).

Somerset Therapeutics LLC voluntarily recalled Atropine Sulfate Ophthalmic Solution, USP 1%, in 5 mL bottles nationwide on Dec. 16, 2024, due to failed impurity specifications, the FDA said. The recall affects 5,870 units distributed across the United States.

How to tell if you have it

  • Brand: Somerset Therapeutics
  • Product: Atropine Sulfate Ophthalmic Solution, USP 1%, 5 mL bottles
  • NDC: 70069-716-01
  • Lot #: A240211
  • Exp. Date: April 2026

The hazard

The product failed impurity specifications because out-of-specification results were observed during long-term stability testing at product expiry, according to the FDA. The recall is classified as Class III.

Context

GovInfoNow's records show Somerset Therapeutics LLC has four other recalls on record since June 4, 2020. Other recent recalls of similar products include a Dexamethasone Injection recall (Feb. 4, 2026), a Cisatracurium Besylate Injection recall (Nov. 26, 2025), and a Haloperidol Injection recall (April 24, 2024). Other recent recalls of similar products include a Fluocinolone Acetonide Solution recall (Dec. 30, 2025), a Clindamycin Phosphate Topical Solution recall (Nov. 26, 2025), and an Atropine Sulfate Injection recall (July 24, 2026).

How to tell if you have this one

Check for the NDC code 70069-716-01 and lot number A240211 on the bottle label. The product is only available by prescription and comes in 5mL bottles.

  • Brand
    Somerset Therapeutics
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Look for NDC 70069-716-01 and lot A240211 on the bottle label.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 6 months after the firm started it.

1. Firm started the recall: Dec 16, 202412. FDA classified it Class III: Dec 31, 202423. Published in FDA’s Enforcement Report: Jan 8, 202534. FDA terminated the recall: Jun 10, 2025420242025
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0169-2025 (December 16, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0169-2025 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA